A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Trial Profile

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Abituzumab (Primary)
  • Indications Systemic scleroderma
  • Focus Therapeutic Use
  • Acronyms STRATUS
  • Sponsors EMD Serono
  • Most Recent Events

    • 09 Sep 2017 According to trial design presented at the 27th Annual Congress of the European Respiratory Society, an interim analysis is planned when 50% of patients have completed 52wks or discontinued prematurely.
    • 09 Sep 2017 Trial design presented at the 27th Annual Congress of the European Respiratory Society.
    • 27 Jul 2017 Planned End Date changed from 31 Oct 2020 to 17 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top